Ferguson Wellman Capital Management Inc. Trims Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Ferguson Wellman Capital Management Inc. decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 110,603 shares of the medical research company's stock after selling 1,416 shares during the period. Thermo Fisher Scientific makes up approximately 1.3% of Ferguson Wellman Capital Management Inc.'s holdings, making the stock its 23rd largest position. Ferguson Wellman Capital Management Inc.'s holdings in Thermo Fisher Scientific were worth $68,416,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Headlands Technologies LLC acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at $32,000. TBH Global Asset Management LLC raised its holdings in Thermo Fisher Scientific by 7.0% during the first quarter. TBH Global Asset Management LLC now owns 671 shares of the medical research company's stock worth $390,000 after purchasing an additional 44 shares in the last quarter. Lord Abbett & CO. LLC boosted its holdings in Thermo Fisher Scientific by 1.9% in the 1st quarter. Lord Abbett & CO. LLC now owns 78,247 shares of the medical research company's stock valued at $45,478,000 after purchasing an additional 1,480 shares in the last quarter. Brighton Jones LLC increased its position in Thermo Fisher Scientific by 5.4% during the 1st quarter. Brighton Jones LLC now owns 4,057 shares of the medical research company's stock worth $2,358,000 after purchasing an additional 209 shares during the period. Finally, Great Lakes Retirement Inc. lifted its holdings in shares of Thermo Fisher Scientific by 1.2% in the 1st quarter. Great Lakes Retirement Inc. now owns 4,446 shares of the medical research company's stock valued at $2,584,000 after buying an additional 53 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the sale, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,175,513.68. This trade represents a 7.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the sale, the senior vice president now directly owns 12,736 shares of the company's stock, valued at $7,134,197.76. This trade represents a 13.57 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 37,150 shares of company stock worth $20,651,865. 0.34% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of recent analyst reports. Bernstein Bank raised their target price on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a "market perform" rating in a report on Tuesday, October 22nd. Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an "overweight" rating for the company in a research note on Thursday, October 24th. TD Cowen increased their target price on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. UBS Group raised Thermo Fisher Scientific to a "strong-buy" rating in a research note on Monday, September 16th. Finally, Stifel Nicolaus dropped their price objective on Thermo Fisher Scientific from $680.00 to $665.00 and set a "buy" rating for the company in a research note on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $649.33.

Thermo Fisher Scientific Trading Down 1.6 %

Shares of NYSE:TMO traded down $8.88 during midday trading on Thursday, reaching $533.02. The company's stock had a trading volume of 1,747,398 shares, compared to its average volume of 1,462,991. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The firm has a market cap of $203.88 billion, a price-to-earnings ratio of 33.78, a price-to-earnings-growth ratio of 3.57 and a beta of 0.79. The business has a 50 day moving average price of $589.87 and a 200 day moving average price of $583.04. Thermo Fisher Scientific Inc. has a 1 year low of $463.99 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. Thermo Fisher Scientific's revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.69 earnings per share. Research analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be paid a dividend of $0.39 per share. The ex-dividend date is Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.29%. Thermo Fisher Scientific's dividend payout ratio is presently 9.78%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.